Edwards Lifesciences announces CFO retirement

Published on:

IRVINE, CA May 14, 2013 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Thomas M. Abate, the company's chief financial officer, plans to retire later this year. Abate, who turns 60 in August, plans to remain CFO until his successor is in place. The company has retained Peter Crist of Crist/Kolder Associates to assist in the CFO search.

"Tom has had a very productive 31-year career with our company, and I want to thank him for his many significant contributions to our success," said Michael A. Mussallem, Edwards' chairman and CEO. "Tom played an important role in establishing Edwards as a standalone company following our spinoff from Baxter Healthcare Corporation in 2000. He has been a valuable business partner and has been instrumental in helping us adapt to an evolving financial landscape, while also positioning the company for the future. His dedication to Edwards has been exemplary, and we look forward to his continued leadership through this transition."

Abate became Edwards' CFO in January 2006. Previously, he was the company's vice president and controller, a position he had held since Edwards became an independent company. In the 18 years prior, Abate was with Baxter in other finance-related positions.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring, enabling them to save and enhance lives. Additional company information can be found at edwards.com.

Related Content

How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
9 key takeaways from AHA 2024 in Chicago
Redo TAVR: The impact of implanting balloon-expandable valves in failed self-expanding valves
Edoxaban could limit blood clots, ‘make life easier’ for heart valve surgery patients

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."